GSK Flu: 2019-2020 season

GSK offers two flu vaccines that enable providers to use the same 0.5-mL dose for all recommended individuals.

<table>
<thead>
<tr>
<th>Vaccine*</th>
<th>Presentation</th>
<th>Age Group (Indication)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluarix Quadrivalent</td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td>≥ 6 months</td>
</tr>
<tr>
<td>FluLaval Quadrivalent</td>
<td>0.5-mL prefilled, single-dose syringe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5-mL multidose vial (ten 0.5-mL doses)</td>
<td></td>
</tr>
</tbody>
</table>

*Fluarix and FluLaval are registered trademarks of the GSK group of companies.
GSK Flu
Offering a Simplified approach to prebooking, ordering and procurement

Continued investments in a state of the art eCommerce platform to simplify the flu process

- Early reservations: Simplified with automatic prebook
- Inventory management: Simplified with flexible delivery
- Contracting: Simplified with eDeclaration forms

GSK Flu
Reliable manufacturer of quadrivalent influenza vaccines

Two manufacturing sites producing flu vaccines with the same 0.5mL 6 month+ indication help provide confidence in Reliable supply.

Continued investments in the US distribution network help provide confidence in Reliable and consistent delivery throughout the flu season.
GSK Flu: 2019-2020 season

GSK expects to supply approximately 40-45 million doses across both seasonal quadrivalent influenza vaccines for the US market in the 2019-20 season.**

**Final quantities will depend upon demand & production capabilities

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

– Do not administer FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
– If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks
– Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
– If FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

- In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)

- Vaccination with FLULAVAL QUADRIVALENT or FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients
Thank you!